SoftBank founder Masayoshi Son speaks in futuristic terms about his company, but the success of his late-stage VC fund is still unknown.Technologyread more
Reports of Tesla vehicles spontaneously catching fire could make customers wary of EVs just as the industry ramps up production plans.Autosread more
Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
The 2019 PGA Championship wraps up on Sunday, May 19. Here's how much money the champion will earn.Earnread more
Trump's relationships with Deutsche Bank have drawn scrutiny in Congress and elsewhere. Trump sued the bank last month to prevent it from complying with Congressional...Financeread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
The move comes after star runner Alysia Montaño's May 12 op-ed in the New York Times in which she detailed her experiences with Nike.Retailread more
The outrage has even inspired a Change.org petition called "Remake Game of Thrones Season 8 with competent writers," with over half-a-million signatories and climbing.Entertainmentread more
While the prolonged fight has been devastating to an already-struggling agriculture industry, there's little indication Trump is paying a political price.Traderead more
* Takeda sells dry eye drug to Novartis for up to $5.3 bln
* Takeda looking to sell $10 bln worth of non-core assets
* Xiidra deal due to close later this year (Adds Takeda's divestment plan, share move)
TOKYO, May 9 (Reuters) - Takeda Pharmaceutical Co Ltd agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of Britain's Shire.
Japan's biggest drugmaker aims to dispose of $10 billion worth of assets to cut debt taken on for the huge Shire acquisition sealed in January, which catapulted it into the world's top 10 drugmakers by sales but also made it one of the most indebted.
The sale of Shire's Xiidra dry eye treatment is likely to close in the second half of 2019, Takeda and Novartis said in a statement.
Xiidra, approved to treat signs and symptoms of dry eye in the United States, Canada and Australia, would bolster Novartis' front-of-the-eye portfolio, the Swiss drugmaker said.
Dry eye occurs when tears fail to provide adequate lubrication, and if left untreated, can become extremely painful, leading to permanent damage to the cornea and vision. It affects an estimated 34 million people in the United States, Novartis' statement showed.
Novartis said it would take on about 400 employees associated with Xiidra, which earned about $400 million of revenue in 2018.
Takeda also said it is selling TachoSil, a surgical patch for bleeding control, to Ethicon for about $400 million.
Takeda's shares rose as much as 3.3 percent in early trading on Thursday. (Reporting by Takashi Umekawa in Tokyo, Tamara Mathias and Arundhati Sarkar in Bengaluru; Editing by Leslie Adler and Sonali Paul)